SETD4 Confers Cancer Stem Cell Chemoresistance in Nonsmall Cell Lung Cancer Patients via the Epigenetic Regulation of Cellular Quiescence

Figure 3

The proportion of SETD4-defined qLCSCs was correlated with chemoresistance in clinical lung cancer patients. (a) Representative IF images of SETD4 in chemotherapy-resistant patients and chemotherapy-sensitive patients. DAPI, nuclear counterstaining. Scale bar, 20 μm. (b) Proportion of SETD4-positive cells in chemotherapy-resistant patients () and chemotherapy-sensitive patients (). The data are presented as the . . (c) Comparison of progression-free survival (PFS) between SETD4 high () and SETD4 low () patients (). Patients were divided into SETD4-high and SETD4 low cohorts according to the median proportion of SETD4-positive cells (0.32%). The median PFS of the SETD4 high and SETD4-low cohorts was 2.3 and 5.8 months, respectively. (d) Correlation between the proportion of SETD4-positive cells and PFS. Pearson analysis showed that the proportion of SETD4-positive cells was negatively correlated with PFS (, ). (e) Representative chest CT images of 2 chemotherapy-resistant patients and 2 chemotherapy-sensitive patients and the corresponding IF images of SETD4.

(a)

(b)

(c)

(d)

(e)